tamsulosin + mirabegron (Kyungdong Pharmaceutical)

KDF1905 is a fixed-dose combination (FDC) small molecule therapy developed by Kyungdong Pharmaceutical for the treatment of urological disorders. It is specifically indicated for patients with benign prostatic hyperplasia (BPH) who also experience symptoms of overactive bladder (OAB). The drug combines tamsulosin hydrochloride, an alpha-1 adrenergic receptor antagonist that reduces urethral resistance by relaxing smooth muscle in the prostate and bladder neck, with mirabegron, a beta-3 adrenergic receptor agonist that improves bladder storage capacity by relaxing the detrusor muscle. This dual mechanism addresses both voiding and storage symptoms, providing a comprehensive treatment option for complex lower urinary tract symptoms (LUTS).

Brand names

Uromira-T

Other names

tamsulosin hydrochloride + mirabegron